Clinical Trials Browser

Active not recruiting × asciminib × Other hematologic neoplasm × Clear all

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

406 enrolled 18 charts 1 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-02-06

ASSURE-3

Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06427811 2025-10-16

ASC4INDIA

Phase 4 Active not recruiting

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05384587 2025-10-14

ASC2ESCALATE

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05413915 2025-05-21

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03906292 2025-03-10

CMLXI

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive